Recombinant Pvs48/45 antigen expressed in E. Coli generates antibodies that block malaria transmission in anopheles albimanus mosquitoes

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Arévalo Herrera, Myriam ^a,c   Vallejo, Andrés F ^b   Rubiano, Kelly ^a,b   Solarte, Yezid ^c   Marin, Catherin ^d   Castellanos, Angélica ^d   Céspedes, Nora ^a   Herrera, Sócrates ^a,b,d  

^a Malaria Vaccine and Drug Development Center   (Colombia)

^b Caucaseco Scientific Research Center   (Colombia)

^c UNIVERSIDAD DEL VALLE   (Colombia)

^d Primate Center Foundation (FUCEP)   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G ANTIBODY; MALARIA VACCINE; MEMBRANE ANTIGEN; PARASITE ANTIBODY; PLASMODIUM VIVAX PROTEIN; PROTEIN ANTIBODY; PVS48 45 ANTIBODY; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; RECOMBINANT PVS48 45 ANTIGEN; RECOMBINANT PVS48 45 PROTEIN; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; PARASITE ANTIGEN; PROTOZOON ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOPHELES; ANOPHELES ALBIMANUS; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; ENDEMIC DISEASE; ESCHERICHIA COLI; GAMETOCYTE; HAPLORHINI; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MALARIA CONTROL; MALE; MOUSE; NONHUMAN; ORTHOLOGY; PARASITE TRANSMISSION; PLASMODIUM VIVAX MALARIA; PROTEIN EXPRESSION; VACCINE PRODUCTION; ANIMAL; AOTIDAE; BAGG ALBINO MOUSE; GENETICS; IMMUNOLOGY; MALARIA, VIVAX; METABOLISM; PARASITOLOGY; PLASMODIUM VIVAX; TRANSMISSION; VETERINARY;

ANIMALIA; ANOPHELES (GENUS); ANOPHELES ALBIMANUS; ESCHERICHIA COLI; MUS; PLASMODIUM VIVAX;

ANIMALS; ANOPHELES; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; AOTIDAE; EPITOPES; ESCHERICHIA COLI; HAPLORHINI; HUMANS; IMMUNOGLOBULIN G; MALARIA VACCINES; MALARIA, VIVAX; MALE; MICE; MICE, INBRED BALB C; PLASMODIUM VIVAX; RECOMBINANT PROTEINS;

EID: 84925238953     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119838     Document Type: Article

References (46)

1. WHO (2013) World malaria report. World Health Organization Geneva. Available: http://www.who.int/malaria/publications/world-malaria-report-2013/report/en/
2. Baird J (1998) Age dependent characteristics of protection v. susceptibility to Plasmodium falciparum. Ann Trop Med Parasitol 92: 367-390. PMID: 9683890
3. Snow RW, Omumbo JA, Lowe B, Molyneux CS, Obiero J-O, et al. (1997) Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet 349: 1650-1654. PMID: 9186382
4. Doolan DL, Dobano C, Baird JK (2009) Acquired immunity to malaria. Clin Microbiol Rev 22: 13-36. doi: 10.1128/CMR.00025-08 PMID: 19136431
5. Mendis C, Munesinghe YD, de Silva YNY, Keragalla I, Carter R (1987) Malaria transmisison-blocking immunity induced by natural infections of Plasmodium vivax in humans. Infect Immun 55: 369-372. PMID: 2879793
6. Grotendorst CA, Kumar N, Carter R, Kaushal DC (1984) A surface protein expressed during the transformation of zygotes of Plasmodium gallinaceum is a target of transmission-blocking antibodies. Infect Immun 45: 775-777. PMID: 6540756
7. Kaushal DC, Carter R, Rener J, Grotendorst CA, Miller LH, et al. (1983) Monoclonal antibodies against surface determinants on gametes of Plasmodium gallinaceum block transmission of malaria parasites to mosquitoes. J Immunol. 131: 2557-2562. PMID: 6631012
8. Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot JS, et al. (2000) Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun 68: 6618-6623. PMID: 11083773
9. Kubler-Kielb J, Majadly F, Wu Y, Narum DL, Guo C, et al. (2007) Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc Natl Acad Sci 104: 293-298. PMID: 17190797
10. Collins WE, Barnwell JW, Sullivan JS, Nace D, Williams T, et al. (2006) Assessment of transmissionblocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees. Am J Trop Med Hyg 74: 215-221. PMID: 16474073
11. Arevalo-Herrera M, Solarte Y, Yasnot MF, Castellanos A, Rincon A, et al. (2005) Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade Pvs 25 recombinant protein. Am J Trop Med Hyg 73: 32-37. PMID: 16291764
12. Arevalo-Herrera M, Solarte Y, Zamora F, Mendez F, Yasnot MF, et al. (2005) Plasmodium vivax: Transmission-blocking immunity in a malaria-endemic area of Colombia. Am J Trop Med Hyg 73: 38-43. PMID: 16291765
13. Bousema T, Roeffen W, Meijerink H, Mwerinde H, Mwakalinga S, et al. (2010) The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania. PLoS One 5: e14114. doi: 10.1371/journal.pone.0014114 PMID: 21124765
14. Gamage-Mendis AC, Rajakaruna J, Carter R, Mendis KN (1992) Transmission blocking immunity to human Plasmodium vivax malaria in an endemic population in Kataragama, Sri Lanka. Parasite Immunol 14: 385-396. PMID: 1437231
15. Tachibana M, Sato C, Otsuki H, Sattabongkot J, Kaneko O, et al. (2012) Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate. Vaccine 30: 1807-1812. doi: 10.1016/j. vaccine.2012.01.003 PMID: 22245309
16. Outchkourov NS, Roeffen W, Kaan A, Jansen J, Luty A, et al. (2008) Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice. Proc Natl Acad Sci U S A 105: 4301-4305. doi: 10.1073/pnas.0800459105 PMID: 18332422
17. Chowdhury DR, Angov E, Kariuki T, Kumar N (2009) A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS One 4: e6352. doi: 10.1371/journal.pone.0006352 PMID: 19623257
18. Barr PJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA, et al. (1991) Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J Exp Med 174: 1203-1208. PMID: 1940798
19. Kaslow DC, Bathurst IC, Lensen T, Ponnudurai T, Barr PJ, et al. (1994) Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect Immun 62: 5576-5580. PMID: 7960139
20. Carter R, Graves P, Keister D, Quakyi I (1990) Properties of epitopes of Pfs 48/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum. Parasite Immunol 12: 587-603. PMID: 1707506
21. Mulder B, Lensen T, Tchuinkam T, Roeffen W, Verhave JP, et al. (1999) Plasmodium falciparum: Membrane Feeding Assays and Competition ELISAs for the Measurement of Transmission Reduction in Sera from Cameroon. Exp Parasitol 92: 81-86. PMID: 10329369
22. Roeffen W, Mulder B, Teelen K, Bolmer M, Eling W, et al. (1996) Association between anti-Pfs48/45 reactivity and P. falciparum transmission-blocking activity in sera from Cameroon. Parasite Immunol 18: 103-109. PMID: 9223163
23. van Dijk MR, Janse CJ, Thompson J, Waters AP, Braks JA, et al. (2001) A central role for P48/45 in malaria parasite male gamete fertility. Cell 104: 153-164. PMID: 11163248
24. Pradel G (2007) Proteins of the malaria parasite sexual stages: expression, function and potential for transmission blocking strategies. Parasitology 134: 1911-1929. PMID: 17714601
25. Arevalo-Herrera M, Solarte Y, Yasnot MF, Castellanos A, Rincon A, et al. (2005) Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein. Am J Trop Med Hyg 73: 32-37. PMID: 16291764
26. Blagborough AM, Yoshida S, Sattabongkot J, Tsuboi T, Sinden RE (2010) Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission. Vaccine 28: 6014-6020. doi: 10.1016/j.vaccine.2010.06.100 PMID: 20637303
27. Kaslow DC, Shiloach J (1994) Production, purification and immunogenicity of a malaria transmissionblocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose. Nat Biotechnol 12: 494-499
28. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, et al. (2008) Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 3: e2636. doi: 10.1371/journal.pone.0002636 PMID: 18612426
29. Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, et al. (2005) Phase 1 vaccine trial of Pvs25H: A transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23: 3131-3138. PMID: 15837212
30. Carter R, Coulson A, Bhatti S, Taylor BJ, Elliott JF (1995) Predicted disulfide-bonded structures for three uniquely related proteins of Plasmodium falciparum, Pfs230, Pfs4845 and Pf12. Mol Biochem Parasitol 71: 203-210. PMID: 7477102
31. Baneyx F, Mujacic M (2004) Recombinant protein folding and misfolding in Escherichia coli. Nat Biotechnol 22: 1399-1408. PMID: 15529165
32. Alcalá P, Ferrer-Miralles N, Villaverde A (2003) Engineering of Escherichia coli ß-galactosidase for solvent display of a functional scFv antibody fragment. FEBS Letters 533: 115-118. PMID: 12505169
33. Collins WE (1994) Aotus The Owl Monkey. London: Academic Press, INC
34. Resources IoLA (1985) Guide for the care and use of laboratory animals: National Academies
35. Gaspar P, Oliveira JL, Frommlet J, Santos MA, Moura G (2012) Eugene: maximizing synthetic gene design for heterologous expression. Bioinformatics 28: 2683-2684. doi: 10.1093/bioinformatics/bts465 PMID: 22847936
36. Hall TA (1999) BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT; 1999. pp. 95-98
37. Shevchenko A (2001) Evaluation of the efficiency of in-gel digestion of proteins by peptide isotopic labeling and MALDI mass spectrometry. Anal Biochem 296: 279-283. PMID: 11554724
38. Blake M, Johnston K, Russell-Jones G, Gotschlich E (1984) A rapid, sensitive method for detection of alkaline phosphatase-conjugated anti-antibody on Western blots. Anal Biochem 136: 175-179. PMID: 6424501
39. AVMA (2013) AVMA Guidelines for the Euthanasia of Animals. In: Association AVM, editor. Schaumburg: Am Vet Med Assoc. pp. 102
40. Herrera S, Gomez A, Vera O, Vergara J, Valderrama-Aguirre A, et al. (2005) Antibody response to Plasmodium vivax antigens in Fy-negative individuals from the Colombian Pacific coast. Am J Trop Med Hyg 73: 44-49. PMID: 16291766
41. Terpe K (2006) Overview of bacterial expression systems for heterologous protein production: From molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol 72: 211-222. PMID: 16791589
42. Doug Chung D-W, Ponts N, Cervantes S, Le Roch KG (2009) Post-translational modifications in Plasmodium: More than you think!. Mol Biochem Parasitol 168: 123-134. doi: 10.1016/j.molbiopara.2009. 08.001 PMID: 19666057
43. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, et al. (2008) Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature 455: 757-763. doi: 10.1038/nature07327 PMID: 18843361
44. Pain A, Hertz-Fowler C (2009) Plasmodium genomics: Latest milestone. Nat Rev Microbiol 7: 180-181. doi: 10.1038/nrmicro2096 PMID: 19219050
45. Sahdev S, Khattar SK, Saini KS (2008) Production of active eukaryotic proteins through bacterial expression systems: A review of the existing biotechnology strategies. Mol Cell Biochem 307: 249-264. PMID: 17874175
46. Birkholtz LM, Blatch G, Coetzer TL, Hoppe HC, Human E, et al. (2008) Heterologous expression of plasmodial proteins for structural studies and functional annotation. Malar J 7: 197. doi: 10.1186/1475-2875-7-197 PMID: 18828893